Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients
Soluble PD-L1 (sPD-L1) levels have been identified as a potential biomarker for various cancers, but its diagnostic and prognostic value in urinary bladder cancer (BC) remains to be fully elucidated. In this study, we investigated sPD-L1 levels in serum and urine samples from 132 patients with BC an...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/22/5841 |
| _version_ | 1797510948599103488 |
|---|---|
| author | Anders Vikerfors Sabina Davidsson Janusz Frey Tomas Jerlström Jessica Carlsson |
| author_facet | Anders Vikerfors Sabina Davidsson Janusz Frey Tomas Jerlström Jessica Carlsson |
| author_sort | Anders Vikerfors |
| collection | DOAJ |
| description | Soluble PD-L1 (sPD-L1) levels have been identified as a potential biomarker for various cancers, but its diagnostic and prognostic value in urinary bladder cancer (BC) remains to be fully elucidated. In this study, we investigated sPD-L1 levels in serum and urine samples from 132 patients with BC and compared them to 51 patients with hematuria (controls). The levels of sPD-L1 in serum and urine were determined using ELISA. Soluble PD-L1 could be detected in 99.5% of the serum samples and 34.4% of the urine samples. Patients diagnosed with BC had significantly higher urinary levels of sPD-L1, compared to controls, however no difference were found in serum sPD-L1 levels (<i>p</i> = 0.038 and <i>p</i> = 0.61, respectively). Significantly higher serum sPD-L1 levels were found in patients with muscle invasive disease and metastatic disease, compared to patients with non-muscle invasive BC and non-metastatic disease (<i>p</i> < 0.05). There was also a trend for higher urine sPD-L1 levels in patients with metastatic disease, compared to patients with non-metastatic disease (<i>p</i> = 0.05). The results from this study suggest that sPD-L1 in serum, but not in urine, could be a potential prognostic biomarker for patients with BC. |
| first_indexed | 2024-03-10T05:38:28Z |
| format | Article |
| id | doaj.art-8a2c402c2c944a3eaaf685f978113a8a |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T05:38:28Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-8a2c402c2c944a3eaaf685f978113a8a2023-11-22T22:44:04ZengMDPI AGCancers2072-66942021-11-011322584110.3390/cancers13225841Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer PatientsAnders Vikerfors0Sabina Davidsson1Janusz Frey2Tomas Jerlström3Jessica Carlsson4Department of Urology, Faculty of Medicine and Health, Örebro University, 703 62 Örebro, SwedenDepartment of Urology, Faculty of Medicine and Health, Örebro University, 703 62 Örebro, SwedenDepartment of Urology, Faculty of Medicine and Health, Örebro University, 703 62 Örebro, SwedenDepartment of Urology, Faculty of Medicine and Health, Örebro University, 703 62 Örebro, SwedenDepartment of Urology, Faculty of Medicine and Health, Örebro University, 703 62 Örebro, SwedenSoluble PD-L1 (sPD-L1) levels have been identified as a potential biomarker for various cancers, but its diagnostic and prognostic value in urinary bladder cancer (BC) remains to be fully elucidated. In this study, we investigated sPD-L1 levels in serum and urine samples from 132 patients with BC and compared them to 51 patients with hematuria (controls). The levels of sPD-L1 in serum and urine were determined using ELISA. Soluble PD-L1 could be detected in 99.5% of the serum samples and 34.4% of the urine samples. Patients diagnosed with BC had significantly higher urinary levels of sPD-L1, compared to controls, however no difference were found in serum sPD-L1 levels (<i>p</i> = 0.038 and <i>p</i> = 0.61, respectively). Significantly higher serum sPD-L1 levels were found in patients with muscle invasive disease and metastatic disease, compared to patients with non-muscle invasive BC and non-metastatic disease (<i>p</i> < 0.05). There was also a trend for higher urine sPD-L1 levels in patients with metastatic disease, compared to patients with non-metastatic disease (<i>p</i> = 0.05). The results from this study suggest that sPD-L1 in serum, but not in urine, could be a potential prognostic biomarker for patients with BC.https://www.mdpi.com/2072-6694/13/22/5841urinary bladder cancermacroscopic hematuriasoluble PD-L1serumurine |
| spellingShingle | Anders Vikerfors Sabina Davidsson Janusz Frey Tomas Jerlström Jessica Carlsson Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients Cancers urinary bladder cancer macroscopic hematuria soluble PD-L1 serum urine |
| title | Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients |
| title_full | Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients |
| title_fullStr | Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients |
| title_full_unstemmed | Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients |
| title_short | Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients |
| title_sort | soluble pd l1 in serum and urine in urinary bladder cancer patients |
| topic | urinary bladder cancer macroscopic hematuria soluble PD-L1 serum urine |
| url | https://www.mdpi.com/2072-6694/13/22/5841 |
| work_keys_str_mv | AT andersvikerfors solublepdl1inserumandurineinurinarybladdercancerpatients AT sabinadavidsson solublepdl1inserumandurineinurinarybladdercancerpatients AT januszfrey solublepdl1inserumandurineinurinarybladdercancerpatients AT tomasjerlstrom solublepdl1inserumandurineinurinarybladdercancerpatients AT jessicacarlsson solublepdl1inserumandurineinurinarybladdercancerpatients |